Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics

By Takashi Ebisawa

A third-party probe into a scandal surrounding Xarelto (rivaroxaban) patient surveys wrapped up earlier this month, laying bare a series of problems inside Osaka-based Bayer Yakuhin, the Japan pharma unit Bayer AG. For one, there was a lack of employee ethics as professionals dealing with drugs closely tied to people’s health. Two, there also seems to have been the malfunctioning of internal divisions, including medical affairs. The company should carry out reforms to thwart the recurrence of the issue - as repeatedly pledged by President Heike Prinz during her press conference. Here’s the chronology of events that has been exposed so far ...